Clinical Trials
Ongoing and Open to Enrolment
SIRIUS-SLE 1: A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus
Investigators: Dr. J Antonio Aviña-Zubieta, Dr. Jennifer Reynolds, Dr. Azin Ahrari
Sponsor: Novartis Pharmaceuticals Inc.
Summary: The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE). More information.
Please send referrals to (604) 875-4321, indicated “ATTN: SIRIUS-SLE Clinical Trial”
SIRIUS-LN: A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis
Investigators: Dr. J Antonio Aviña-Zubieta, Dr. Jennifer Reynolds, Dr. Monica Beaulieu
Sponsor: Novartis Pharmaceuticals Inc.
Summary: This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN. More information.
Please send referrals to (604) 875-4321, indicated “ATTN: SIRIUS-LN Clinical Trial”
POETYK SjS-1: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome
Investigators: Dr. Alice Y Mai, Dr. Raheem B Kherani, Dr. Sonia N Yeung, Dr. Michael Nimmo
Sponsor: Bristol Myers Squibb
Summary: The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren’s Syndrome. More information.
Please send referrals to (604) 875-4321, indicated “ATTN: POETYK Clinical Trial”
DAISY: A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis
Investigators: Dr. Hyein Kim, Dr. Kun Huang,Dr. James V Dunne
Sponsor: Astra-Zeneca
Summary: The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud’s phenomenon symptom. More information.
Please send referrals to (604) 875-4321, indicated “ATTN: DAISY Clinical Trial”
Ongoing and Closed to Enrolment
NEPTUNUS-2: A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren’s Syndrome
Investigators: Dr. Raheem B Kherani, Dr. Alice Y Mai
Sponsor: Novartis Pharmaceuticals, Inc
Summary: Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjogren’s syndrome. The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of ianalumab (VAY736) administered subcutaneously (s.c.) monthly or every 3 months compared to placebo in patients with active Sjogren’s syndrome. More information.
Prospective Clinical Research
Ongoing and Open to Enrolment
INTACT: RetINal Toxicity And HydroxyChloroquine Therapy Study
Investigators: Dr. J Antonio Aviña-Zubieta, Dr. John M Esdaile, Dr. Hyon Choi, Dr. Linda Li, Dr. Hui Xie, Dr. Diane V Lacaille, Dr. Kamran Shojania, Dr. Mahyar Etminan, Dr. David Maberley, Dr. Martin Dawes
Summary: The INTACT study is a 5-year longitudinal study that is following Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) patients in BC who are currently taking and have been taking Hydroxychloroquine (HCQ) for ≥5 years, with the goal of finding the risk of retinal toxicity as a result of long term HCQ therapy. More information.
Please send referrals to (604) 207-4059 using the INTACT referral form (also available on the Plexia Store and Accuro Repository).
POET: Low Barrier Rheumatology Clinic at Pender Community Health Centre and Outreach Study
Investigators: Dr. Daksh Choudhary, Dr. Brent Ohata, Dr. Alec Yu
Summary: The POET study tests whether offering either a $20 honorarium per follow-up visit or a specialized rheumatology outreach program improves engagement in care for patients with active inflammatory arthritis who get their primary care at specific Vancouver Coastal Health Community Health Centers. The goal of the study is to assess whether these interventions improve engagement in care. More information.
For more Infomation please contact 604-349-5817
VIVA: Virtual Intervention for Vertebral frActure: a Pilot, Feasibility Study for a Multicentre Randomized Controlled Trial
Investigators: Dr. Lora Giangregorio, Dr. Raheem B Kherani, Dr. Alexandra Pappaioanou, Dr. Jennifer Watt
Summary: Spine fractures, common due to osteoporosis, occur during falls or daily activities. They cause pain lasting long periods, affecting breathing, appetite, digestion, and mobility, limiting work and daily activities. Standard rehabilitation programs lack accessibility, especially in rural areas, and healthcare providers specializing in spine fractures are scarce. After reviewing research and consulting patients and healthcare providers, a virtual rehabilitation program for people with spine fractures, called VIVA, was developed. A multicenter trial will investigate VIVA’s feasibility in adults with spine fractures in Ontario, British Columbia, and Quebec. Secondary outcomes include physical function, balance, pain, fear of movement, falls, falls self-efficacy, quality of life, mood, nutrition risk, and physical activity. Adults over 50 with at least one spine fracture in the past two years due to osteoporosis will be recruited. Participants will receive either immediate VIVA intervention or delayed receipt 10 weeks post-randomization. The VIVA intervention involves weekly 1:1 rehabilitation sessions with an exercise professional for eight weeks. More information.
Please email viva@arthritisresearch.ca to enrol a patient.